Skip Navigation LinksHome > February 19, 2008 - Volume 22 - Issue 4 > The role of protective HCP5 and HLA-C associated polymorphis...
AIDS:
doi: 10.1097/QAD.0b013e3282f470e4
Research Letters

The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors

Han, Yefei; Lai, Jun; Barditch-Crovo, Patricia; Gallant, Joel E; Williams, Thomas M; Siliciano, Robert F; Blankson, Joel N

Free Access
Article Outline
Collapse Box

Author Information

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Received 24 October, 2007

Revised 31 October, 2007

Accepted 13 November, 2007

Collapse Box

Abstract

Elite suppressors (ES) are untreated HIV-1-infected patients who maintain undetectable viral loads. A recent whole-genome analysis identified two independent polymorphisms associated with low viral loads in untreated HIV-1 infection. We screened 16 ES; none were positive for the protective HLA complex 5 gene polymorphism, and only four were positive for the protective polymorphism associated with the HLA-C gene. These results suggest that some ES control viremia by mechanisms independent of the newly-identified genetic factors.

The mechanisms by which elite suppressors (ES) control viral replication remain unclear. Although several studies [1,2] have shown that some may be infected with a defective virus, we recently demonstrated that some ES are infected with a fully replication-competent virus [3]. This strongly suggests that host factors play a role in the control of viral replication. The HLA-B*57 and HLA-B*27 [4–7] alleles are over-represented among ES, which has been interpreted as evidence for a role of CD8+ T cells in the control of viremia. Support for this hypothesis came from multiple studies showing that HIV-1-specific CD8+ T cells from ES were qualitatively superior to those from patients with progressive disease [8–13].

However, a recent genome-wide screen has identified single nucleotide polymorphisms (SNP) in two genes that are associated with low viral loads in untreated patients [14]. The protective SNP in one of the genes, HLA complex P5 (HCP5), is in strong linkage disequilibrium with the HLA-B*5701 allele [14]. It is thus possible that the HCP5 polymorphism and not HLA-B*5701 plays a direct role in the control of viremia, and that the qualitatively superior HLA-B*57-restricted CD8+ T cell functions observed in ES are a result, rather than a cause, of the control of viral replication. On the other hand, the other protective polymorphism, associated with the HLA-C gene [14], may control expression levels of HLA-C proteins and thus enhance presentation of HIV-1-specific antigens. To determine the role of these polymorphisms in the control of HIV-1 replication in ES, we performed genotypic analysis on peripheral blood mononuclear cells from 19 patients.

The target SNPs were amplified from genomic DNA by polymerase chain reaction (PCR) reactions using locus-specific primers. The primers used for detecting the HCP SNP were HCP5-F1: TAC CCT CAT TGT GTG ACA GCA, and HCP5-R1: GTC GTG GGA TTT TGC ACT TC. The primers used for detecting the HLA-C associated SNP were HLA-C-F2: AGG GTG GTG CCA AGT ATG AG, and HLA-C-R2: CTT CTA GAG CCC CGT GGA G. The PCR conditions used included denaturation at 94 °C for 3 min, followed by 30 cycles of 94 °C for 30 s, 60 °C for 30 s, and 68 °C for 30 s. Polymorphisms were detected by sequence analysis of gel-purified PCR products (Qiagen, Valencia, California, USA). All heterozygous SNPs were confirmed by cloning.

As shown in the Table 1, nine ES were positive for the HLA-B*5703 allele and one was HLA-B*5702-positive. Both alleles are closely related to HLA-B*5701, which was found to be in strong linkage disequilibrium with the protective HCP5 SNP. It is thus surprising that none of the HLA-B*5702/5703 ES were positive for the protective HCP5 allele. By contrast, the protective allele was present in an HLA-B*5701 patient with a low but detectable viral load and an HLA-B*5701 patient with progressive disease. One of 16 ES was homozygous and three others were heterozygous for the protective HLA-C-associated SNP. This allele has a relatively high frequency in Sub-Saharan Africans and thus would be expected to be relatively common in our African–American cohort of patients. A chi-square analysis showed that the observed frequency in our patients of African descent who are homozygous (0.07) and heterozygous (0.143) for the protective SNP is not significantly different from that expected based on the frequencies observed in a cohort of Sub-Saharan African patients (0.07 and 0.368, respectively) in the NCBI database (q = 0.48). This is not a perfect analysis because African–American patients may have significant genetic differences from Sub-Saharan Africans and, although these data need to be confirmed in a larger cohort of ES, the preliminary data suggest that the protective allele cannot explain the control of viremia in the majority of our patients.

Table 1
Table 1
Image Tools

It is interesting that 12 of the 16 patients controlled viral replication without having either of the two protective SNPs with the highest impact on viral load in untreated patients. In addition, three of four patients (ES4, ES8 and ES10) from whom we have isolated replication-competent virus in the past [3] were negative for both protective alleles. Thus, there are clearly some patients who are able to control pathogenic HIV-1 without HCP5 or the HLA-C associated polymorphisms.

It is unclear why none of our HLA-B*5703-positive ES expressed the protective HCP5 allele. The frequency of this allele in the NCBI database is very low in Sub-Saharan Africans and thus would also be expected to be also low in our cohort, which is predominantly comprised of patients of African descent. Of note, one African-American HLA-B*5701+ patient with progressive disease was positive for this HCP5 protective allele. Further analysis is warranted to determine whether the lack of the protective HCP5 allele in our cohort is due to the predominance of African–American patients or the lack of HLA-B*5701 patients. There may also be other genes in linkage disequilibrium with HLA-B*5703 that play a major role in the control of viral replication in these patients. It will thus be important to perform genome-wide analyses in cohorts of patients of African descent.

The clinical history of Progressor # 2 (P2) has features that argue both for and against a role for genetic factors other than HLA-B*57 in the control of viral replication. This HLA-B*5703 patient, who has neither the HCP5- or HLA-C-associated protective SNPs, completely controlled a pathogenic CXCR4-tropic HIV-1 isolate shortly after primary infection [15]. This control may have occurred before an adaptive cellular immune response could have developed. Furthermore, the low frequency of latently infected cells observed shortly after seroconversion suggests that he never had high levels of viremia [15]. This is consistent with a strong initial innate immune response. However, he experienced a virologic breakthrough 12 months after seroconversion. Full viral genome sequencing before and after viremia revealed only changes in two HLA-B*57-restricted CD8+ T cell epitopes, reversions of the M184V drug resistance mutation and a novel Vpu mutation. The M184V reversion was not accompanied by a major increase in viral fitness, so it is unclear how any of these mutations would affect an innate response. On the other hand, the temporal relationship between the development of the escape mutations and virologic breakthrough strongly suggests a role of the adaptive immune response in the control of viremia. Further studies will be needed to determine how much of a role other genetic factors play in the control of viral replication in HLA-B*5703-positive ES.

Back to Top | Article Outline

Acknowledgements

Funded by NIH Grants K08 AI51191-04 and R56 AI73185-01A1 and the Howard Hughes Medical Institute. We thank Dr Rafael Irizarry for helpful discussions.

Back to Top | Article Outline

References

1. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, et al. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995; 270:988–991.

2. Alexander L, Weiskopf E, Greenough TC, Gaddis NC, Auerbach MR, Malim MH, et al. Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection. J Virol 2000; 74:4361–4376.

3. Blankson JN, Bailey JR, Thayil S, Yang HC, Lassen K, Lai J, et al. Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. J Virol 2007; 81:2508–2518.

4. Kaslow RA, Carrington M, Apple R, Park L, Munoz A, Saah AJ, et al. Influence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat Med 1996; 2:405–411.

5. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci USA 2000; 97:2709–2714.

6. Lambotte O, Boufassa F, Madec Y, Nguyen A, Goujard C, Meyer L, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis 2005; 41:1053–1056.

7. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769–775.

8. Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061–1068.

9. Emu B, Sinclair E, Favre D, Moretto WJ, Hsue P, Hoh R, et al. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J Virol 2005; 79:14169–14178.

10. Betts MR, Nason MC, West SM, De Rosa SC, Migueles SA, Abraham J, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T-cells. Blood 2006; 107:4781–4789.

11. Addo MM, Draenert R, Rathod A, Verrill CL, Davis BT, Gandhi RT, et al. Fully differentiated HIV-1 specific CD8+ T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2007; 2:E321.

12. Saez-Cirion A, Lacabaratz C, Lambotte O, Versmisse P, Urrutia A, Boufassa F, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc Natl Acad Sci USA 2007; 104:6776–6781.

13. Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204:2473–2485.

14. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944–947.

15. Bailey JR, Zhang H, Wegweiser BW, Yang HC, Herrera L, Ahonkhai A, et al. Evolution of HIV-1 in an HLA-B*57-positive patient during virologic escape. J Infect Dis 2007; 196:50–55.

Cited By:

This article has been cited 20 time(s).

Pharmacogenomics Journal
A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients
Tohkin, M; Kaniwa, N; Saito, Y; Sugiyama, E; Kurose, K; Nishikawa, J; Hasegawa, R; Aihara, M; Matsunaga, K; Abe, M; Furuya, H; Takahashi, Y; Ikeda, H; Muramatsu, M; Ueta, M; Sotozono, C; Kinoshita, S; Ikezawa, Z
Pharmacogenomics Journal, 13(1): 60-69.
10.1038/tpj.2011.41
CrossRef
Plos Pathogens
Cytotoxic Capacity of SIV-Specific CD8(+) T Cells against Primary Autologous Targets Correlates with Immune Control in SIV-Infected Rhesus Macaques
Mendoza, D; Migueles, SA; Rood, JE; Peterson, B; Johnson, S; Doria-Rose, N; Schneider, D; Rakasz, E; Trivett, MT; Trubey, CM; Coalter, V; Hallahan, CW; Watkins, D; Franchini, G; Lifson, JD; Connors, M
Plos Pathogens, 9(2): -.
ARTN e1003195
CrossRef
Retrovirology
Primary CD8(+) T cells from elite suppressors effectively eliminate non-productively HIV-1 infected resting and activated CD4(+) T cells
Buckheit, RW; Siliciano, RF; Blankson, JN
Retrovirology, 10(): -.
ARTN 68
CrossRef
Plos One
Genetic Variability in Markers of HLA-C Expression in Two Diverse South African Populations
Gentle, NL; Paximadis, M; Puren, A; Tiemessen, CT
Plos One, 8(7): -.
ARTN e67780
CrossRef
Genes and Immunity
The HLA-B/-C haplotype block contains major determinants for host control of HIV
Trachtenberg, E; Bhattacharya, T; Ladner, M; Phair, J; Erlich, H; Wolinsky, S
Genes and Immunity, 10(8): 673-677.
10.1038/gene.2009.58
CrossRef
Plos One
HIV-1 Disease-Influencing Effects Associated with ZNRD1, HCP5 and HLA-C Alleles Are Attributable Mainly to Either HLA-A10 or HLA-B*57 Alleles
Catano, G; Kulkarni, H; He, W; Marconi, VC; Agan, BK; Landrum, M; Anderson, S; Delmar, J; Telles, V; Song, L; Castiblanco, J; Clark, RA; Dolan, MJ; Ahuja, SK
Plos One, 3(): -.
ARTN e3636
CrossRef
Antiviral Research
Effector mechanisms in HIV-1 infected elite controllers: Highly active immune responses?
Blankson, JN
Antiviral Research, 85(1): 295-302.
10.1016/j.antiviral.2009.08.007
CrossRef
Journal of Virology
Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor
Bailey, JR; O'Connell, K; Yang, HC; Han, Y; Xu, J; Jilek, B; Williams, TM; Ray, SC; Siliciano, RF; Blankson, JN
Journal of Virology, 82(): 7395-7410.
10.1128/JVI.00800-08
CrossRef
Journal of Virology
Control of HIV-1 in Elite Suppressors despite Ongoing Replication and Evolution in Plasma Virus
O'Connell, KA; Brennan, TP; Bailey, JR; Ray, SC; Siliciano, RF; Blankson, JN
Journal of Virology, 84(): 7018-7028.
10.1128/JVI.00548-10
CrossRef
Journal of Virology
Role of Natural Killer Cells in a Cohort of Elite Suppressors: Low Frequency of the Protective KIR3DS1 Allele and Limited Inhibition of Human Immunodeficiency Virus Type 1 Replication In Vitro
O'Connell, KA; Han, YF; Williams, TM; Siliciano, RF; Blankson, JN
Journal of Virology, 83(): 5028-5034.
10.1128/JVI.02551-08
CrossRef
Trends in Pharmacological Sciences
Elucidating the elite: mechanisms of control in HIV-1 infection
O'Connell, KA; Bailey, JR; Blankson, JN
Trends in Pharmacological Sciences, 30(): 631-637.
10.1016/j.tips.2009.09.005
CrossRef
Journal of Virology
Effective Downregulation of HLA-A*2 and HLA-B*57 by Primary Human Immunodeficiency Virus Type 1 Isolates Cultured from Elite Suppressors
Nou, E; Zhou, Y; Nou, DD; Blankson, JN
Journal of Virology, 83(): 6941-6946.
10.1128/JVI.00306-09
CrossRef
Plos Genetics
Common Genetic Variation and the Control of HIV-1 in Humans
Fellay, J; Ge, DL; Shianna, KV; Colombo, S; Ledergerber, B; Cirulli, ET; Urban, TJ; Zhang, KL; Gumbs, CE; Smith, JP; Castagna, A; Cozzi-Lepri, A; De Luca, A; Easterbrook, P; Gunthard, HF; Mallal, S; Mussini, C; Dalmau, J; Martinez-Picado, J; Miro, JM; Obel, N; Wolinsky, SM; Martinson, JJ; Detels, R; Margolick, JB; Jacobson, LP; Descombes, P; Antonarakis, SE; Beckmann, JS; O'Brien, SJ; Letvin, NL; McMichael, AJ; Haynes, BF; Carrington, M; Feng, S; Telenti, A; Goldstein, DB
Plos Genetics, 5(): -.
ARTN e1000791
CrossRef
Expert Opinion on Biological Therapy
Elite control of HIV infection: implications for vaccine design
Baker, BM; Block, BL; Rothchild, AC; Walker, BD
Expert Opinion on Biological Therapy, 9(1): 55-69.
10.1517/14712590802571928
CrossRef
Cell Host & Microbe
Identifying host targets for drug development with knowledge from genome-wide studies: Lessons from HIV-AIDS
Winkler, CA
Cell Host & Microbe, 3(4): 203-205.
10.1016/j.chom.2008.04.001
CrossRef
Journal of Virology
Evidence of CD8(+) T-Cell-Mediated Selective Pressure on Human Immunodeficiency Virus Type 1 nef in HLA-B*57(+) Elite Suppressors
Bailey, JR; Brennan, TP; O'Connell, KA; Siliciano, RF; Blankson, JN
Journal of Virology, 83(1): 88-97.
10.1128/JVI.01958-08
CrossRef
Cellular and Molecular Life Sciences
The implications of viral reservoirs on the elite control of HIV-1 infection
Buckheit, RW; Salgado, M; Martins, KO; Blankson, JN
Cellular and Molecular Life Sciences, 70(6): 1009-1019.
10.1007/s00018-012-1101-7
CrossRef
AIDS
A polymorphism in the HCP5 gene associated with HLA-B*5701 does not restrict HIV-1 in vitro
Yoon, W; Ma, B; Fellay, J; Huang, W; Xia, S; Zhang, R; Shianna, KV; Liao, H; Haynes, BF; Goldstein, DB; the NIAID Center for HIV/AIDS Vaccine Immunology,
AIDS, 24(1): 155-157.
10.1097/QAD.0b013e32833202f5
PDF (469) | CrossRef
AIDS
Host genetics and HIV-1 viral load set-point in African–Americans
Shrestha, S; Aissani, B; Song, W; Wilson, CM; Kaslow, RA; Tang, J
AIDS, 23(6): 673-677.
10.1097/QAD.0b013e328325d414
PDF (114) | CrossRef
JAIDS Journal of Acquired Immune Deficiency Syndromes
Epidemiologic Characteristics and Natural History of HIV-1 Natural Viral Suppressors
Sajadi, MM; Constantine, NT; Mann, DL; Charurat, M; Dadzan, E; Kadlecik, P; Redfield, RR
JAIDS Journal of Acquired Immune Deficiency Syndromes, 50(4): 403-408.
10.1097/QAI.0b013e3181945f1e
PDF (158) | CrossRef
Back to Top | Article Outline

© 2008 Lippincott Williams & Wilkins, Inc.

Login